Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade) [Seeking Alpha]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Seeking Alpha
CPRX's AGAMREE launch outpaces expectations, with 115% Y/Y revenue growth and strong DMD center adoption, while FYCOMPA faces ongoing generic erosion. The company's business model relies on high margins, disciplined business development, and minimal internal R&D, supported by $689.9 million in cash and no debt. My DCF model suggests CPRX is undervalued by ~26%, but future returns hinge on sustained mid-single-digit growth, durable IP, and prudent capital allocation. NiseriN/iStock via Getty Images Introduction Today, I am revisiting Catalyst Pharmaceuticals, Inc. CPRX ). I last wrote about this company in September 2024. Things were looking bleak at that time. Catalyst's flagship drug, FIRDAPSE, appeared to be on the verge of This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? [Yahoo! Finance]Yahoo! Finance
- A Fresh Look at Catalyst Pharmaceuticals (CPRX) Valuation Following Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceGlobeNewswire
- Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™GlobeNewswire
- Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare ConferenceGlobeNewswire
CPRX
Earnings
- 11/5/25 - Beat
CPRX
Sec Filings
- 12/3/25 - Form 4
- 11/28/25 - Form 4
- 11/26/25 - Form 144
- CPRX's page on the SEC website